SPECIFIC AIMS The CHAVI-ID Operations and Management Support Component, (OMSC) will serve as a resource to the entire CHAVI-ID, providing overall management, coordination and supervision ofthe program. The CHAVI-ID director, Bart Haynes will serve as the leader of the OMSC, and experienced OMSC staff will be responsible for managing and coordinating the entire range of CHAVI-ID activities, monitoring progress and ensuring that the CHAVI-ID Scientific Agenda and Strategic Plan is developed, renewed, and implemented effectively and efficiently.
Specific Aims will include the following.
Aim 1. Provide overall management, coordination and supervision of programs within CHAVI-ID to optimally facilitate HIV-1 vaccine discovery and development.
Aim 2. Ensure timely financial accounting in CHAVI-ID Aim 3. Ensure compliance with all institutional and federal research guidelines. Management of the CHAVI-ID will require remarkably complex and timely coordination of finances, program management, facilities, research and development activities, and investigators across disciplines and institutions. The expertise this group has gained over the past 6 years in CHAVI, will ensure success in the management of CHAVI-ID.
Effective and timely financial and programmatic management are the key to the success for any scientific consortium. Ensuring the management of individual scientific projects, and having the ability to redirect funds in a timely manner as dictated by the science will facilitate HIV-1 vaccine development.
|Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221|
|Arakelyan, Anush; Fitzgerald, Wendy; King, Deborah F et al. (2017) Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. Sci Rep 7:948|
|Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:|
|Verkoczy, Laurent; Alt, Frederick W; Tian, Ming (2017) Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev 275:89-107|
|Haynes, Barton F; Mascola, John R (2017) The quest for an antibody-based HIV vaccine. Immunol Rev 275:5-10|
|Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng et al. (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145-160|
|Kelsoe, Garnett; Haynes, Barton F (2017) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol :|
|Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:|
|Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431|
|Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107|
Showing the most recent 10 out of 220 publications